ss-31 protocol: Frequently asked questions

Administer SS-31 30–60 minutes before the session, not after. Cardiolipin oxidation and cristae destabilization occur during sustained aerobic stress. Once mitochondrial membrane damage accumulates, post-exercise administration cannot reverse it. The peptide's mechanism is protective, not reparative. One small study found no improvement in next-day recovery markers when SS-31 was given immediately post-exercise compared to placebo, consistent with the finding that mitochondrial damage must be prevented rather than treated after the fact.

Either your training volume is insufficient to produce measurable mitochondrial stress, or your baseline mitochondrial function is already highly adapted. SS-31 cannot improve what is not limiting performance. Re-evaluate your protocol: are you using it on sessions where oxidative load is genuinely high (3+ hours at moderate-to-high intensity), or are you administering it before short interval sessions where mitochondrial stress is minimal? If you are using appropriate doses (15–20mg) on genuinely high-load sessions and still observe no benefit, discontinue the protocol. Some athletes show no measurable response, particularly those with years of high-volume endurance training already under their belt.

Skip the missed dose and continue your protocol. Do not double-dose on the next session. SS-31 does not produce cumulative training adaptations that require uninterrupted dosing; it preserves mitochondrial function during acute oxidative stress. Missing one dose means that session's oxidative load is unmitigated, but it does not impair your response to future doses. Athletes who miss doses during high-volume weeks report noticeably harder late-session efforts and longer recovery times, which aligns with the peptide's mitochondrial protective effect being session-specific rather than systemic.

Assess NAD+ and NADH levels directly. Preventing oxidative damage does not restore depleted energy substrates. If ATP synthesis remains impaired despite reduced superoxide production, the bottleneck is upstream in NAD+-dependent dehydrogenases or electron transport complex assembly. NAD+ precursors or mitochondrial biogenesis stimulators (AMPK activators, exercise) address this axis.

Evaluate mitochondrial DNA integrity and protein import machinery. If mtDNA deletions exceed 60% or TOM/TIM complex function is impaired, neither NAD+ nor SS-31 will restore capacity because the mitochondria lack the genetic and protein infrastructure to utilise them. At this stage, mitophagy induction or mitochondrial transplantation research becomes relevant.

Measure cardiolipin oxidation and cristae morphology via electron microscopy. NAD+ repletion cannot reverse structural membrane damage. If oxidative stress markers (4-HNE, MDA) remain elevated despite normalised NAD+/NADH ratios, the limiting factor is membrane integrity, not substrate availability. SS-31 or alternative cardiolipin-protective interventions may be required.

Rotate injection sites more aggressively and reduce injection volume per site. Both MOTS-c and SS-31 are pH-neutral when reconstituted properly, but subcutaneous peptide injections can cause localized inflammation if the same site is used repeatedly within a 72-hour window. If redness persists beyond 48 hours, spreads beyond the injection site, or is accompanied by warmth or fever, discontinue injections and consult a physician. Those are signs of infection, not peptide sensitivity. Standard site rotation (abdomen Monday/Thursday, left thigh Tuesday/Friday, right thigh Wednesday/Saturday) minimizes cumulative irritation.

If the ambient temperature was below 25°C and the exposure was less than 12 hours, the peptides are likely still usable. But potency degradation is possible. If the temperature exceeded 25°C or the vials were left out for more than 24 hours, discard them. Protein denaturation is irreversible, and there's no visual or olfactory test for peptide potency loss. The conservative approach: if you're uncertain about storage conditions, replace the vial. Injecting degraded peptides isn't harmful, but it wastes the dose and creates false negatives in efficacy assessment.

Continue the protocol for at least 8 weeks before assessing efficacy. Mitochondrial biogenesis. The creation of new mitochondria. Takes 4–6 weeks to produce measurable increases in mitochondrial density, and functional ATP output improvements lag structural changes by another 2–4 weeks. A 2019 study in Aging Cell found that MOTS-c-induced changes in skeletal muscle gene expression peaked at week 6, not week 2. Subjective energy levels are a lagging indicator. If you're tracking biomarkers like lactate clearance, VO2 max, or resting metabolic rate, those will shift before you feel different.